<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23653">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02798861</url>
  </required_header>
  <id_info>
    <org_study_id>204560</org_study_id>
    <nct_id>NCT02798861</nct_id>
  </id_info>
  <brief_title>Controlled Attenuation Parameter (CAP) in Liver Allografts</brief_title>
  <official_title>Usefulness of Controlled Attenuation Parameter (CAP) for the Assessment of Liver Steatosis in Liver Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim is to determine the accuracy of CAP in the quantification of liver steatosis
      using liver biopsies as reference. Secondarily, investigators will correlate transient
      elastography (TE) and CAP results, analyze possible associations between CAP/TE and
      post-liver transplant (LT) clinical outcomes, and evaluate the change in CAP after LT. The
      study aims to include as many donors as needed to achieve 100 transplanted liver allografts.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Controlled Attenuation Parameter (CAP) - Accuracy</measure>
    <time_frame>Change from Baseline (pre-procurement) to 6 months post liver transplant</time_frame>
    <description>CAP accuracy in quantification of liver steatosis to be determined using liver biopsies as reference</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver Transplant</condition>
  <condition>Liver Steatosis</condition>
  <condition>Liver Disease</condition>
  <condition>Primary Non-function</condition>
  <condition>Early Allograft Dysfunction</condition>
  <arm_group>
    <arm_group_label>CAP assessment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Controlled Attenuation Parameter with Fibroscan 530/502 before liver procurement and after liver transplantation to assess steatosis, and its association with clinical outcomes</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fibroscan 530/502</intervention_name>
    <description>Fibroscan 530/502 obtained before procurement in the donor and at 3 to 6 months post-transplant in the liver recipient.</description>
    <arm_group_label>CAP assessment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria - Liver Recipient

          -  Men and women, Age 18-years old to 80-years old inclusive

        Inclusion criteria - Liver Donor

          -  Valid TE with Fibroscan 530/502, defined as:

               -  At least 10 valid measurements

               -  IQR/Median stiffness value &lt;30% (only in cases with &gt;7.1 kPa)

        Exclusion criteria - Liver Recipient

          -  Patient did not undergo liver transplantation

        Exclusion criteria - Liver Donor

          -  Donation after circulatory death (DCD)

          -  Donor receiving vasoactive amines

          -  ALT or AST &gt;300

          -  No liver biopsy obtained during organ procurement process
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andres Duarte-Rojo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 8, 2016</lastchanged_date>
  <firstreceived_date>June 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
